Dr. Ravi Kant obtained his Master’s degree in Medical-Biotechnology from the All India Institute of Medical Science, New Delhi (2006-08) and Doctorate in Immunology from the National Institute of Immunology, New Delhi (2008-14). As part of his Ph.D. thesis project, he developed novel peptide analogs of myelin basic protein (MBP)85-99, tested their therapeutic activities in-vitro and in experimental mice with autoimmune encephalomyelitis, a model for Multiple Sclerosis. He extended his research in the area of autoimmune diseases and have worked at premier institutions like Indian Institute of Science, Bangalore (2014-16), Scripps Research Institute, San Diego (2016-18), and Technische Universitat Munchen, Germany (2019-21). During his doctoral and postdoctoral studies, he has been focusing on various immunological and vascular changes that take place in the central nervous system of mice with autoimmune encephalomyelitis.
Fellowships awarded/availed: CSIR JRF-NET (2008-13), DBT-JRF (2008&09), GATE (2008), DBT-PG fellowship (2006-08), Merit scholarship (2000-02).